Last edition
News about "Human Metapneumovirus (hMPV) "
Clover Biopharmaceuticals Completes Initial Enrollment in Phase II Trial of RSV Combination Vaccines
The Australia-based Phase II study is evaluating Clover’s protein-based combination vaccine candidates SCB-1022 and SCB-1033 targeting RSV, hMPV and PIV3 in older adults, using its proprietary Trimer-Tag technology.
Human Metapneumovirus (hMPV) | 12/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members